剪接体突变对HMA联合VEN治疗AML结局的影响
该回顾性队列研究纳入119例接受HMA+VEN治疗的AML患者,比较剪接体突变(39例)与野生型(80例)的结局。IDH2突变在SRSF2突变患者中富集且与良好结局相关,RAS突变在U2AF1突变患者中富集且与不良结局相关。
要点
- 剪接体突变与野生型患者接受HMA+VEN的缓解率和生存无显著差异
- SRSF2突变患者中IDH2共突变与有利结局相关
- U2AF1突变患者中RAS共突变与不良结局相关
核心结论
- 接受HMA+VEN治疗的AML患者中,剪接体突变与野生型患者的结局相当,特定共突变组合显示有利结局。
研究设计与样本
- 回顾性队列分析,纳入美国德克萨斯大学MD安德森癌症中心接受HMA+VEN为基础方案治疗的119例患者(剪接体突变39例,野生型80例)。
主要发现
- SRSF2、SF3B1和U2AF1突变患者的中位OS分别为未达到、35个月和8个月。
- IDH2突变在SRSF2突变患者中富集,与有利结局相关(1年和2年OS分别为100%和88%)。
- RAS突变在U2AF1突变患者中富集,与不良结局相关(中位OS 8个月)。
临床怎么用
- 对于携带剪接体突变的AML患者,HMA+VEN方案可考虑作为治疗选择之一。
- 共突变分析(如IDH2、RAS)有助于进一步风险分层和预后评估。
局限性
- 回顾性研究设计,样本量有限,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spliceosome mutations (SRSF2, SF3B1, U2AF1, ZRSR2), are encountered in ∼50% of secondary acute myeloid leukemia cases (sAML) and define a molecular subgroup with outcomes similar to sAML in de novo AML patients treated with intensive chemotherapy. Outcomes in patients with spliceosome mutations treated with hypomethylating agents in combination with venetoclax (HMA+VEN) remains unknown. The primary objective was to compare outcomes in patients with spliceosome mutations vs wild-type patients treated with HMA+VEN. Secondary objectives included analysis of the mutational landscape of the spliceosome cohort and assessing the impact of co-occurring mutations. We performed a retrospective cohort analysis of patients treated with HMA+VEN-based regimens at The University of Texas MD Anderson Cancer Center. A total of 119 patients (spliceosome mutated n = 39 [SRSF2, n = 24; SF3B1, n = 8; U2AF1, n = 7]; wild-type, n = 80) were included. Similar responses were observed between spliceosome and wild-type cohorts for composite complete response (CRc; 79% vs 75%, P = .65), and measurable residual disease-negative CRc (48% vs 60%, P = .34). Median overall survival for spliceosome vs wild-type patients was 35 vs 14 months (P = .58), and was not reached; 35 months and 8 months for patients with SRSF2, SF3B1, and U2AF1 mutations, respectively. IDH2 mutations were enriched in patients with SRSF2 mutations and associated with favorable outcomes (1- and 2-year overall survival [OS] of 100% and 88%). RAS mutations were enriched in patients with U2AF1 mutations and associated with inferior outcomes (median OS, 8 months). Comparable outcomes were observed between patients with vs without spliceosome mutations treated with HMA+VEN regimens, with specific co-mutation pairs demonstrating favorable outcomes.
引用
- Lachowiez CA, Loghavi S, Furudate K, et al. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021. PMID: 33885753. doi:10.1182/bloodadvances.2020004173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。